Dengue virus type 4 (DENV-4) is the fourth of the four serotypes of dengue virus, an enveloped, positive-sense single-stranded RNA virus in the genus Flavivirus that causes dengue fever. It is primarily transmitted by Aedes aegypti and Aedes albopictus mosquitoes.
Genome and Virology
Like the other dengue viruses, DENV-4 has a positive-sense RNA genome of about 10.7 kb encoding a single open reading frame. Translation of the genome yields a polyprotein that is cleaved into three structural proteins—capsid, premembrane/membrane and envelope—and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5). The envelope glycoprotein binds to cellular receptors such as DC‑SIGN and heparan sulfate, allowing entry via receptor-mediated endocytosis; acidification of the endosome triggers membrane fusion and release of the genome. Replication occurs on endoplasmic reticulum membranes where NS3 acts as a protease and helicase and NS5 functions as the RNA-dependent RNA polymerase and methyltransferase. New virions assemble within the endoplasmic reticulum, mature in the Golgi and exit through exocytosis. DENV-4 infects dendritic cells, monocytes and endothelial cells in humans and replicates in mosquito midgut and salivary glands. Two major genotypes (I and II) have been described, each with distinct geographic distribution.
Outbreaks and Observations
DENV-4 was first isolated in the Philippines in 1953 and has historically caused fewer outbreaks than the other serotypes, but it remains clinically important. It was responsible for epidemics in the Caribbean and northern South America during the 1980s and early 2000s, including large outbreaks in Brazil, Venezuela and Puerto Rico. In Asia, genotype II circulates endemically in Southeast Asia and the Pacific, while genotype I emerged in Brazil around 2010, highlighting the potential for introduction and spread into naïve populations. Clinical presentation ranges from asymptomatic infection to classic dengue fever with high fever, headache, myalgia, arthralgia and rash. Although DENV-4 is generally associated with milder disease, severe dengue can occur, especially in individuals with secondary infection by a heterologous serotype, due to antibody-dependent enhancement. Public health measures focus on vector control, elimination of breeding sites and targeted vaccination campaigns. Dengue virus type 4 remains part of the complex landscape of dengue epidemiology. Continued surveillance of its genotypes and integration of vector management and vaccine strategies are essential to reduce the burden of dengue worldwide. Related Terms: Dengue Virus 1, Dengue Virus 2, Dengue Virus 3, Flavivirus, Aedes mosquitoes